Fidelity Investments’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-15,274
| Closed | -$86.6K | – | 5568 |
|
|
2025
Q3 | $86.6K | Buy |
15,274
+1,547
| +11% | +$7.92K | ﹤0.01% | 3726 |
|
|
2025
Q2 | $52.3K | Buy |
13,727
+12,022
| +705% | +$37.3K | ﹤0.01% | 3877 |
|
|
2025
Q1 | $4.48K | Sell |
1,705
-4,729
| -74% | -$15.4K | ﹤0.01% | 4732 |
|
|
2024
Q4 | $22.8K | Buy |
6,434
+3,454
| +116% | +$13.2K | ﹤0.01% | 4159 |
|
|
2024
Q3 | $13.6K | Buy |
2,980
+816
| +38% | +$3.95K | ﹤0.01% | 4335 |
|
|
2024
Q2 | $9.41K | Sell |
2,164
-813
| -27% | -$3.57K | ﹤0.01% | 4349 |
|
|
2024
Q1 | $14.9K | Sell |
2,977
-769
| -21% | -$4.31K | ﹤0.01% | 4133 |
|
|
2023
Q4 | $23.5K | Buy |
3,746
+2,990
| +396% | +$17.1K | ﹤0.01% | 3862 |
|
|
2023
Q3 | $5.38K | Sell |
756
-13
| -2% | -$102 | ﹤0.01% | 4314 |
|
|
2023
Q2 | $7.84K | Buy |
769
+54
| +8% | +$564 | ﹤0.01% | 4226 |
|
|
2023
Q1 | $6.49K | Hold |
715
| – | – | ﹤0.01% | 4302 |
|
|
2022
Q4 | $5.13K | Hold |
715
| – | – | ﹤0.01% | 4242 |
|
|
2022
Q3 | $5K | Hold |
715
| – | – | ﹤0.01% | 4331 |
|
|
2022
Q2 | $3K | Sell |
715
-174
| -20% | -$861 | ﹤0.01% | 4487 |
|
|
2022
Q1 | $5K | Buy |
+889
| New | +$4.37K | ﹤0.01% | 4446 |
|
|
2018
Q2 | – | Sell |
-200,000
| Closed | -$2.48M | – | 2693 |
|
|
2018
Q1 | $2.48M | Hold |
200,000
| – | – | ﹤0.01% | 2327 |
|
|
2017
Q4 | $2.42M | Buy |
+200,000
| New | +$2.82M | ﹤0.01% | 2317 |
|
Fidelity Investments's SCPH Position: Q4 2025 in Review
Fidelity Investments sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 15,274 shares — an estimated $86.6K sold.
Fidelity Investments first reported a position in SCPH in Q4 2017 and held it in 17 quarters. The position peaked at $2.48M in Q1 2018. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Fidelity Investments reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Fidelity Investments sold 15,274 scPharmaceuticals shares in Q4 2025, an estimated $86.6K.
- Fidelity Investments first reported a position in scPharmaceuticals in Q4 2017 and held it in 17 quarters.
- Fidelity Investments's scPharmaceuticals position peaked at $2.48M in Q1 2018.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.